Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.
about
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipientsLimitations of medical research and evidence at the patient-clinician encounter scaleIs personality a key predictor of missing study data? An analysis from a randomized controlled trialEffectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposalIndividualizing endpoints in randomized clinical trials to better inform individual patient care: the TARGET proposalMultimorbidity and evidence generationInforming evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseasesSubgroup analyses in confirmatory clinical trials: time to be specific about their purposesDevelopment of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney diseasePrognosis Research Strategy (PROGRESS) 3: prognostic model researchComputational modeling for bedside application.Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohortsBig data analytics to improve cardiovascular care: promise and challenges.Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741Current progress in patient-specific modeling.Diabetes and poor disease control: is comorbid depression associated with poor medication adherence or lack of treatment intensification?Secondary failure of metformin monotherapy in clinical practice.Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines.Development of a clinical prediction algorithm for knee osteoarthritis structural progression in a cohort study: value of adding measurement of subchondral bone densityConceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized MedicineIndividualized medical decision making: necessary, achievable, but not yet attainable.Tiotropium might improve survival in subjects with COPD at high risk of mortality.Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges.The influence of non-clinical patient factors on medical oncologists' decisions to recommend breast cancer adjuvant chemotherapyNo child left behind: Enrolling children and adults simultaneously in critical care randomized trialsRisk of thiazide-induced metabolic adverse events in older adults.Current Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care.Detecting moderator effects using subgroup analyses.Group analysis versus individual response: the inferential limits of randomized controlled trialsDesigning a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction.Subgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantationGuiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity.Evaluating marker-guided treatment selection strategies.Individual differences and evidence-based psychopharmacologyOutcomes and statistical power in adult critical care randomized trialsSupport of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines.Random treatment assignment using mathematical equipoise for comparative effectiveness trials.
P2860
Q24187213-2F08D797-F485-42EA-BE29-F9A4A74A31EEQ24282606-B3175341-5E1F-4685-87CC-CCB370B0BF57Q24288800-EF75CC0A-8E6B-4AA4-AF55-34C8BBBDA27BQ24288917-CF08EBBA-D9DF-4141-8B92-5070FAA2DEBBQ24288920-BF9B5936-3932-40EB-B0C9-A64A8DF3E300Q26739895-D133D3C0-5920-4505-95D3-7318AAADC3AFQ27014802-4F977C8B-3F50-4D34-998A-F0580BCB7E83Q27023214-224E610B-AED3-42FF-87B9-71A62D57E912Q28067390-91F6603C-025F-49BA-B1BB-C19A16B6FCEBQ28538142-9DF266AC-E863-4FC0-ABC8-E967231187FDQ28709215-CC1284FB-9AED-4B28-B183-9D29F0E65256Q30488539-56C4D5CE-7DBF-4A7A-876A-EC850E4DDD71Q30581769-E294C182-AC9A-4329-95FF-8214B48F10C0Q31062479-38096AEA-8D0D-4D43-A66E-36AF73EA36C1Q31112168-67FAC5F9-7EC8-4ABA-904A-952AB4A27194Q31143342-334E980E-93C4-45DC-81C0-5E2D69D96A39Q33383727-E765A4D3-69DE-4679-A7EA-BD5AAE65862DQ33605053-C14B0ED9-143B-4760-A2D5-5E873CD33703Q33606011-2D1E018E-E786-43BB-AD16-996ED2B60F89Q33683607-92B1BA6E-5F6A-4E5C-92E6-0E4741E3A1C9Q33689688-739E0D5D-5932-4417-BBF5-EB66DD5CED4EQ33692083-E67FD2A1-96D4-42D7-A6B8-6D52B4A64DC4Q33714815-1A152BD4-CEFE-484D-9D87-73F1737D27E4Q33752536-9B0BE9A8-47F6-4C15-9278-37B3EA739D26Q33769268-BB40B7F4-D9FC-4B07-8FFE-14805391E071Q33900204-F20799E6-72C4-484B-A45A-7192A69A04DEQ33910933-2B3B7790-3810-4DF7-BC99-62D327F589DCQ33992275-99888B14-BD0A-4A2D-9EBD-E4AFE7F696F0Q34026623-1FEAFA17-09CB-4213-BC38-BE2B559388D1Q34145173-22B003BF-8818-4EB8-B8A4-DFB87D3AC6BCQ34184426-7CAB3FFD-0463-4BDB-BF2D-F29C106F0D2FQ34192035-9585D8DE-DC65-4CC1-95A7-87D940EB7A20Q34366871-850486E1-3F99-4C3D-8A9A-E93045B84779Q34382549-8DA1BD53-0D1B-4E86-9F62-E76A33329F14Q34418562-DD3304D8-F9D2-420B-87CF-9F117D21D39CQ34422281-D107F3EE-5EB0-427D-9AC6-6BEA4BFA8ED3Q34422763-E6510CA4-3015-454B-8425-039036220344Q34480195-630432AD-3953-4201-BF00-35D6C100A1CBQ34542774-E200F1F1-9D87-4D40-8714-A2AC817B40B2Q34794180-A85FF082-BB4F-48C6-93AD-09D43C6CA1C0
P2860
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Limitations of applying summar ...... need for risk stratification.
@en
Limitations of applying summar ...... need for risk stratification.
@nl
type
label
Limitations of applying summar ...... need for risk stratification.
@en
Limitations of applying summar ...... need for risk stratification.
@nl
prefLabel
Limitations of applying summar ...... need for risk stratification.
@en
Limitations of applying summar ...... need for risk stratification.
@nl
P356
P1476
Limitations of applying summar ...... need for risk stratification.
@en
P2093
David M Kent
Rodney A Hayward
P304
P356
10.1001/JAMA.298.10.1209
P407
P577
2007-09-01T00:00:00Z